MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcjo.2025.10.002

Медицинская библиотека · Canadian journal of ophthalmology. Journal canadien d'ophtalmologie · 2025

Outcomes of 16-week extension of anti-VEGF therapy in neovascular age-related macular degeneration.

Basilious Amy, Yuan Amelia T, Sheidow Tom G

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

To determine the outcomes of extending anti-VEGF injection intervals to 4 months in neovascular age-related macular degeneration (nAMD).

DESIGN

A prospective cohort study.

PARTICIPANTS

Patients undergoing injections with standard-dose anti-VEGF (aflibercept, ranibizumab) with documented disease stability at 3-month injection intervals for ≥2 years.

METHODS

The injection interval was extended to 4 months. The primary outcome of disease stability was defined as no clinical evidence of lesion growth, blood, or intraretinal or new subretinal fluid seen on ocular coherence tomography (OCT). Demographic data, visual acuity, exam findings, and OCT data were collected.

RESULTS

This study included 88 eyes (83.4 ± 7.3 years, 64.8% female) with nAMD extended to injection intervals of 4 months (56 eyes with aflibercept and 32 with ranibizumab). The recurrence rate was 10.2% (9/88). Four eyes recurred after the first 4-month extension interval, 2 eyes at the 8-month follow-up, 2 eyes at 16 months, and 1 eye at 22 months. In eyes with a recurrence (n = 9), there was no significant difference (p > .05) between mean visual acuity prior to recurrence (0.18 ± 0.13 [20/30]) and at final follow-up postrecurrence (0.21 ± 0.17 [20/30]). All but 1 case returned to within 1 Snellen line of visual acuity at final follow-up. All eyes were able to regain stability at 3- or 4-month injection intervals.

CONCLUSIONS

In nAMD patients with disease stability at 3-month injection intervals for at least 2 years, the majority remained stable when extended to 4 months. Recurrences were able to achieve stability again with shorter injection intervals, without a persistent decline in visual acuity.

Для цитирования: Basilious Amy, Yuan Amelia T, Sheidow Tom G. Outcomes of 16-week extension of anti-VEGF therapy in neovascular age-related macular degeneration.. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2025. DOI: 10.1016/j.jcjo.2025.10.002.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.